Drugs / LCAR-AMDR Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05654779 | Dec 2022 → Sep 2023 | acute myeloid leukemia | Institute of Hematology & Blood Diseases Hospital, China | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LCAR-AMDR Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05654779 ↗ |
| Known as | LCAR-AMDR Cells Product | “Biological: LCAR-AMDR Cells Product” NCT05654779 ↗ |